t
Dechra Pharmaceuticals PLC announced on April 1, 2022, an application for admission to the Premium Segment of the Official List. This application is for an additional 2,261 shares for the Save As You Earn (SAYE) Scheme, 150,000 for the 2017 Long Term Incentive Plan, and 80,000 for the Global Save As You Earn 2018 block listings, with admission expected on or around April 7, 2022.
| Date | 1 Apr 2022 |
| Time | 10:56:38 |
| Category | Capital structure |
| ID | 9592G |
1 April 2022
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for the following:
· Additional 2,261 for the Save As You Earn (SAYE) Scheme block listing;
· Additional 150,000 for the 2017 Long Term Incentive Plan block listing;
· Additional 80,000 for the Global Save As You Earn 2018 block listing.
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on or around 7 April 2022.
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: [email protected]
About Dechra
Dechra is a global veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.